Bayer’s development portfolio of cell and gene therapies already comprises seven advanced assets in different stages of clinical development. These are focused on multiple therapeutic areas with high unmet needs such as neurodegenerative, neuromuscular and cardiovascular indications, with leading programs in Pompe disease, Parkinson’s disease, hemophilia A, and congestive heart failure. … [Read more...] about Bayer announces big investment in external innovation
